DAYPRO ALTA Drug Patent Profile

Which patents cover Daypro Alta, and what generic alternatives are available?

Daypro Alta is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in DAYPRO ALTA is oxaprozin potassium. There are thirteen drug master file entries for this compound. Additional details are available on the oxaprozin potassium profile page.

Summary for DAYPRO ALTA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	1
Patent Applications:	118
DailyMed Link:	DAYPRO ALTA at DailyMed

Recent Clinical Trials for DAYPRO ALTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sanford Research	Early Phase 1

See all DAYPRO ALTA clinical trials

US Patents and Regulatory Information for DAYPRO ALTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	DAYPRO ALTA	oxaprozin potassium	TABLET;ORAL	020776-001	Oct 17, 2002		DISCN	No	No

Expired US Patents for DAYPRO ALTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	DAYPRO ALTA	oxaprozin potassium	TABLET;ORAL	020776-001	Oct 17, 2002	6,030,643

International Patents for DAYPRO ALTA

See the table below for patents covering DAYPRO ALTA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20000015865
Spain	2248850
Australia	3059797
Australia	718030
New Zealand	332861	Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
European Patent Office	0901372	FORMULATIONS PHARMACEUTIQUES CONTENANT DU POTASSIUM, DU SODIUM ET DES SELS TRIS D'OXAPROZINE (POTASSIUM, SODIUM AND TRIS OXAPROZIN SALT PHARMACEUTICAL FORMULATIONS)

DAYPRO ALTA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for DAYPRO ALTA

Introduction

DAYPRO ALTA, a nonsteroidal anti-inflammatory drug (NSAID) containing oxaprozin potassium, is used for the treatment of inflammation, pain, fever, and swelling associated with osteoarthritis and rheumatoid arthritis. To understand the market dynamics and financial trajectory of DAYPRO ALTA, it is crucial to examine its clinical efficacy, market positioning, and the broader pharmaceutical industry context.

Clinical Efficacy and Indications

DAYPRO ALTA has been evaluated in several clinical studies for its efficacy in treating osteoarthritis and rheumatoid arthritis. It has shown significant improvement in the signs and symptoms of these conditions, comparable to other NSAIDs like aspirin[1][4].

• Osteoarthritis: In a 6-month placebo-controlled study, DAYPRO ALTA demonstrated improvement in the WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, which includes measures of pain, stiffness, and functional ability[1].
• Rheumatoid Arthritis: DAYPRO ALTA was found to be comparable to high doses of aspirin in relieving the signs and symptoms of rheumatoid arthritis in clinical trials involving over 600 patients[1].

Market Positioning

DAYPRO ALTA competes in the NSAID market, which is a well-established segment within the pharmaceutical industry. The drug's market positioning is influenced by its efficacy, safety profile, and the presence of other NSAIDs.

• Competitive Landscape: The NSAID market is highly competitive, with numerous drugs available for similar indications. DAYPRO ALTA must differentiate itself through its specific benefits, such as its pharmacokinetic profile and side effect profile[1][4].
• Prescription Trends: The prescription trends for DAYPRO ALTA would be influenced by healthcare provider preferences, patient outcomes, and the availability of alternative treatments.

Safety and Tolerability

The safety and tolerability of DAYPRO ALTA are critical factors in its market dynamics.

• Adverse Reactions: DAYPRO ALTA has been associated with gastrointestinal events, such as symptomatic ulcers and nausea, which are common with NSAIDs. It is contraindicated in patients with known hypersensitivity to oxaprozin potassium or other NSAIDs, and it should be used cautiously in patients with a history of asthma or allergic reactions to aspirin[1][4].
• Concomitant Use: The drug's interaction with other medications, such as diuretics, ACE inhibitors, and lithium, must be carefully managed to avoid adverse effects[1][4].

Financial Trajectory

While the financial performance of DAYPRO ALTA itself is not directly reported, understanding the broader financial context of pharmaceutical companies and the market trends can provide insights.

• Revenue Streams: The revenue generated by DAYPRO ALTA would be part of the overall revenue of the pharmaceutical company that manufactures it. This revenue is influenced by factors such as prescription volume, pricing strategies, and market competition.
• Cost Considerations: The cost of developing, manufacturing, and marketing DAYPRO ALTA, as well as the costs associated with managing its side effects and interactions, play a significant role in its financial trajectory.

Industry Trends and Market Performance

The pharmaceutical industry is subject to various trends and regulatory changes that can impact the financial performance of drugs like DAYPRO ALTA.

• Regulatory Environment: Changes in regulatory policies and guidelines can affect the approval, marketing, and use of NSAIDs. For instance, warnings about the risks associated with NSAIDs, such as cardiovascular and gastrointestinal events, can influence prescribing practices[1][4].
• Market Growth: The growth of the NSAID market is influenced by demographic factors, such as an aging population, and the increasing prevalence of conditions like osteoarthritis and rheumatoid arthritis.

Example of Pharmaceutical Company Financials

To illustrate the financial dynamics in the pharmaceutical sector, consider the financial performance of DarioHealth, a company involved in digital health solutions but not directly related to DAYPRO ALTA.

• Revenue Growth: DarioHealth reported a significant increase in revenue, with Q3 2024 revenue reaching $7.42 million, an 18.7% increase from Q2 2024 and a 111% increase compared to Q3 2023. This growth was driven by expansion in B2B2C revenues[2].
• Operating Expenses and Losses: The company also reported a reduction in operating expenses and losses, with a 25.7% decrease in GAAP operating losses and a 33.3% decrease in non-GAAP operating losses compared to Q2 2024. This improvement is attributed to synergies from mergers and cost reduction strategies[2].

Key Takeaways

• Clinical Efficacy: DAYPRO ALTA is effective in treating osteoarthritis and rheumatoid arthritis, with a pharmacokinetic profile that supports once-daily dosing.
• Market Competition: The drug operates in a competitive NSAID market, requiring differentiation through its safety profile and specific benefits.
• Safety and Tolerability: DAYPRO ALTA has a side effect profile typical of NSAIDs, with gastrointestinal events and interactions with other medications being key considerations.
• Financial Performance: The financial trajectory of DAYPRO ALTA is influenced by prescription trends, regulatory environment, and market competition, though direct financial data is not available.

FAQs

1. What are the primary indications for DAYPRO ALTA? DAYPRO ALTA is indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.

2. How does DAYPRO ALTA compare to other NSAIDs in terms of efficacy? DAYPRO ALTA has been shown to be comparable to other NSAIDs, such as aspirin, in relieving the signs and symptoms of osteoarthritis and rheumatoid arthritis.

3. What are the common side effects associated with DAYPRO ALTA? Common side effects include gastrointestinal events like symptomatic ulcers and nausea, as well as potential interactions with other medications.

4. Can DAYPRO ALTA be used concomitantly with other oxaprozin-containing products? No, DAYPRO ALTA should not be used concomitantly with other oxaprozin-containing products due to the risk of increased adverse effects.

5. How does the regulatory environment impact the use of DAYPRO ALTA? Changes in regulatory policies and guidelines, such as warnings about NSAID risks, can influence prescribing practices and the overall market dynamics for DAYPRO ALTA.

Sources

1. FDA Label for DAYPRO ALTA - https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020776s002lbl.pdf
2. DarioHealth Financial and Operating Results - https://www.prnewswire.com/news-releases/dariohealth-reports-third-quarter-2024-financial-and-operating-results-302298557.html
3. RxList: Daypro Alta - https://www.rxlist.com/daypro-alta-drug.htm
4. DarioHealth Investor Room - https://dariohealth.investorroom.com/2024-03-28-DarioHealth-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-and-Operating-Results